US Stock MarketDetailed Quotes

HCM Hutchmed (China)

Watchlist
  • 18.630
  • +0.630+3.50%
Close Nov 1 16:00 ET
  • 18.630
  • 0.0000.00%
Post 16:00 ET
3.25BMarket Cap-84681P/E (TTM)

About Hutchmed (China) Company

HUTCHMED (China) Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People’s Republic of China and Hong Kong. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription pharmaceutical products Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. Surufatinib, an inhibitor for the treatment of neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Hong Kong, China.

Company Profile

SymbolHCM
Company NameHutchmed (China) co.,Ltd.
Listing DateMar 17, 2016
Issue Price13.50
Founded2000
CEODr. Weiguo Su
MarketNASDAQ
Employees1988
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends12-31
AddressCheung Kong Center,2 Queen's Road Central,48th Floor
CityHong Kong,China
ProvinceHK
CountryChina
Phone852-2121-8200

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Weiguo Su
  • Executive Director,Chief Executive Officer and Chief Scientific Officer
  • 4.11M
  • Hong Chen
  • Executive Vice President and Chief Commercial Officer (China)
  • --
  • Dr. Karen Jane Atkin
  • Executive Vice President and Chief Operating Officer
  • --
  • Johnny Cheng Chig FUNG
  • Executive Director,Chief Financial Officer
  • 1.55M
  • Dr. Ming Michael Shi
  • Executive Vice President, Head of R&D and Chief Medical Officer
  • --
  • Dr. Zhenping Wu
  • Senior Vice President, Pharmaceutical Sciences
  • --
  • May Qingmei Wang
  • Senior Vice President, Business Development & Strategic Alliances
  • --
  • Kin Hung Mark Lee
  • Senior Vice President, Corporate Management and Communications
  • --
  • Dan Eldar
  • Non-Executive Director,Chairman
  • 71.00K
  • Dr. Renu Bhatia
  • Non-Executive Director
  • --
  • Edith Shih
  • Non-Executive Director,Company Secretary
  • --
  • Graeme Allan Jack
  • Non-Executive Director
  • 182.00K
  • Edith Shih
  • Non-Executive Director,Company Secretary
  • 71.00K
  • Professor Shu Kam Tony Mok
  • Non-Executive Director
  • 186.00K
  • Ling Yang
  • Non-Executive Director
  • --
  • Paul Rutherford Carter
  • Non-Executive Director,Senior Independent Director
  • 188.00K
  • Charles George Rupert Nixon
  • Group General Counsel
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data